Astrazeneca Share News (AZN)

AstraZeneca reports positive results in latest lung cancer trials

(Sharecast News) - AstraZeneca said on Wednesday that its 'FLAURA2' phase three trial had yielded positive high-level results, demonstrating the potential of 'Tagrisso', or osimertinib, combined with chemotherapy in lung cancer patients.

AstraZeneca to leave leading U.S. drug lobby group

LONDON, May 16 (Reuters) - AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said.

AstraZeneca to leave leading U.S. drug lobby group

LONDON, May 16 (Reuters) - AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said.

UK's FTSE index ends flat; little reaction to BoE rate decision

BoE lifts benchmark rate to 4.5% as expected

*

FTSE 100 slips ahead of BoE decision, ASOS tumbles on weak sales

ASOS records worst day in over 10 months

*

AstraZeneca's Ultomiris approved in EU for autoimmune disease NMOSD

(Alliance News) - AstraZeneca PLC on Wednesday said the European Commission approved its drug Ultomiris in the EU for adults with autoimmune disease neuromyelitis optica spectrum disorder, known as NMOSD.

Director dealings: AstraZeneca CFO makes $1.5m sale, IHG chair buys in

(Sharecast News) - At the top of the list of FTSE 350 director sells on Tuesday was AstraZeneca, whose chief financial officer sold almost $1.5m worth of the company's American depositary shares.

LONDON BROKER RATINGS: RBC raises Intertek; Davy likes Greencoat UK

(Alliance News) - The following London-listed shares received analyst recommendations xxxxday morning:

TOP NEWS: AstraZeneca's Farxiga approved in US to treat heart failure

(Alliance News) - AstraZeneca PLC on Tuesday said its Farxiga drug has been approved by the US Food & Drug Administration to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults.

AstraZeneca's Farxiga heart failure drug gets extended US approval

(Sharecast News) - AstraZeneca's Farxiga drug has been approved in the US to reduce the risk of cardiovascular death, hospitalisation for heart failure and urgent heart failure visits in adults, the company said on Tuesday.

IN BRIEF: AstraZeneca Chair Michel Demare buys GBP230,000 in shares

AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Non-Executive Chair Michel Demare buys 2,000 shares at GBP117.01, worth GBP234,020, on Friday last week.

Director dealings: Genus announces new CEO's compensation, AstraZeneca chair spends £0.23m

(Sharecast News) - Livestock genetics company Genus saw its shares weaken on Tuesday afternoon after it announced the agreed reward arrangements for its incoming CEO, Jorgen Kokke.

AstraZeneca bemoans ODAC judgement on use of Lynparza drug for cancer

(Alliance News) - AstraZeneca PLC on Tuesday bemoaned the results of a regulatory meeting held by the US Food & Drug Administration, which suggested its Lynparza prostate cancer treatment should be limited to tumours with a BRCA mutation.

AstraZeneca 'disappointed' with FDA panel vote on prostate drug

(Sharecast News) - AstraZeneca said it was disappointed with a decision by a panel of US Food and Drug Administration advisers to restrict use of its treatment for a type of prostate cancer.

AstraZeneca "disappointed" with US ODAC's guidance on Lynparza

(Alliance News) - AstraZeneca PLC on Friday said the US Food & Drug Administration's Oncologic Drugs Advisory Committee has recognised a favourable benefit risk profile for its Lynparza, plus abiraterone and prednisone or prednisolone, for the treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer.